Charles River Insiders Sell $32M After Earnings Beat
Charles River Laboratories beat Q2 2026 adjusted EPS by 10.2% while simultaneously cutting full-year EPS guidance in the same August 5 release, with five insiders selling $31.77 million in shares in t
Charles River Insiders Sell $32M After Earnings Beat
NEW YORK, August 17 —
Charles River Laboratories Inte (CRL), which produces research animals, runs preclinical safety studies, and tests sterile pharmaceuticals for biopharma clients worldwide, delivered its largest quarterly earnings beat in four attempts. Five executives then sold $31.77 million in shares within six days. The company cut its full-year 2026 EPS outlook in the same release that printed a 10.2% Q2 beat.
- Q2 2026 adjusted EPS of $3.02 beat the $2.74 consensus by 10.2%, the fourth consecutive quarterly beat.
- Full-year 2026 EPS guidance was simultaneously cut; the stock at $288 already trades above the $281 analyst consensus target.
- $31.77 million in insider selling in 90 days, zero open-market purchases; GAAP EPS is -$4.82, adjusted forward P/E 22.7x.
The Guide Cut That Muddies the Beat
CRL's adjusted EPS of $3.02 beat the $2.74 consensus in Q2, extending a four-quarter streak that began with Q3 2025. That is the record management is presenting. What it is not presenting as prominently: trailing twelve-month revenue has declined 2.7% to $4.00 billion as demand for preclinical services stays under pressure, and the same August 5 filing lowered the full-year 2026 EPS outlook. A company that beats the quarterly bar while cutting the annual target is telling two stories at once. The one measured by the calendar year matters more.
Five Sellers, No Buyers
Director James C. Foster sold 75,000 shares at $225 on June 29, collecting $16.88 million before the August 5 results arrived. After the beat, he sold another 28,733 shares at $275 for $7.90 million, bringing his 90-day total to $24.78 million. CEO Birgit Girshick sold 6,500 shares at $279.90 on August 11 for $1.82 million. CEVP Shannon Parisotto's two post-earnings sales totaling $2.37 million were conducted under a 10b5-1 plan, which limits their signaling value. Foster's June sale carried no such structure. In 90 days across all insiders: $31.77 million out, zero in.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| CRL | $13.8B | 22.7x | +78.4% |
| TECH | $11.3B | 31.2x | +35.9% |
| IQV | $39.5B | 16.6x | +22.9% |
| COO | $14.7B | 15.1x | +3.6% |
| BIO | $9.6B | 35.6x | +25.2% |
| WST | $24.6B | 35.1x | +43.7% |
The Number That Changes the Thesis
At $288, CRL trades above the $281 average analyst target, on a GAAP EPS of -$4.82 and $2.84 billion in net debt. The valuation rests entirely on the 22.7x forward multiple applied to adjusted estimates, worth pressure-testing in the DCF calculator. The number that breaks the bearish case: a restored full-year EPS guide paired with TTM revenue returning to growth. If the next quarterly beat is again followed by an annual downgrade, the streak is no longer a recovery signal. Run the free Charles River Laboratories Inte deep-dive →.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Charles River insiders sell after earnings?
Five executives sold a combined $31.77 million in shares within six days of the August 5 results, with zero open-market purchases across the full 90-day window. Director James C. Foster accounted for $24.78 million across two transactions. His June sale, which preceded the earnings release, carried no 10b5-1 plan structure.
Did Charles River beat Q2 2026 earnings?
Yes. Adjusted EPS of $3.02 beat the $2.74 consensus by 10.2%, extending a streak of four consecutive quarterly beats that began with Q3 2025. The same August 5 filing that reported the beat also lowered the full-year 2026 EPS outlook.
What happened to Charles River full-year 2026 guidance?
The company cut its full-year 2026 EPS guidance in the same release that printed the Q2 beat. Trailing twelve-month revenue has declined 2.7% to $4.00 billion, reflecting sustained pressure on preclinical services demand.
Is Charles River stock overvalued at current prices?
At $288, CRL trades above the $281 average analyst consensus target. The company carries a GAAP EPS of -$4.82 and $2.84 billion in net debt, making the valuation rest entirely on a 22.7x forward multiple applied to adjusted estimates.
What would change the bearish case on Charles River?
The article identifies two conditions: a restored full-year EPS guide paired with trailing twelve-month revenue returning to growth. If the next quarterly beat is again followed by an annual downgrade, the four-quarter streak stops functioning as a recovery signal.
Charles River Laboratories beat adjusted EPS estimates for the fourth consecutive quarter in August 2026, yet within days of the report the CEO, a founding director, and three other executives collectively sold more than $31 million in shares. The simultaneous earnings momentum and C-suite exit raises a question the quarterly numbers alone cannot answer.